ID   ENPP2_HUMAN             Reviewed;         863 AA.
AC   Q13822; A8UHA1; E9PHP7; Q13827; Q14555; Q15117; Q9UCQ8; Q9UCR0;
AC   Q9UCR1; Q9UCR2; Q9UCR3; Q9UCR4;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   02-MAR-2010, sequence version 3.
DT   10-MAY-2017, entry version 161.
DE   RecName: Full=Ectonucleotide pyrophosphatase/phosphodiesterase family member 2;
DE            Short=E-NPP 2;
DE            EC=3.1.4.39;
DE   AltName: Full=Autotaxin;
DE   AltName: Full=Extracellular lysophospholipase D;
DE            Short=LysoPLD;
DE   Flags: Precursor;
GN   Name=ENPP2; Synonyms=ATX, PDNP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), PARTIAL PROTEIN SEQUENCE,
RP   CHARACTERIZATION, AND VARIANT PRO-493.
RC   TISSUE=Melanoma;
RX   PubMed=7982964;
RA   Murata J., Lee H.Y., Clair T., Krutzsch H.C., Arestad A.A.,
RA   Sobel M.E., Liotta L.A., Stracke M.L.;
RT   "cDNA cloning of the human tumor motility-stimulating protein,
RT   autotaxin, reveals a homology with phosphodiesterases.";
RL   J. Biol. Chem. 269:30479-30484(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), NUCLEOTIDE SEQUENCE [GENOMIC
RP   DNA] OF 1-45, TISSUE SPECIFICITY, AND VARIANT PRO-493.
RX   PubMed=8586446; DOI=10.1006/geno.1995.0036;
RA   Kawagoe H., Soma O., Goji J., Nishimura N., Narita M., Inazawa J.,
RA   Nakamura H., Sano K.;
RT   "Molecular cloning and chromosomal assignment of the human brain-type
RT   phosphodiesterase I/nucleotide pyrophosphatase gene (PDNP2).";
RL   Genomics 30:380-384(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND
RP   VARIANT PRO-493.
RC   TISSUE=Teratocarcinoma;
RX   PubMed=8579579; DOI=10.1006/bbrc.1996.0127;
RA   Lee H.Y., Murata J., Clair T., Polymeropoulos M.H., Torres R.,
RA   Manrow R.E., Liotta L.A., Stracke M.L.;
RT   "Cloning, chromosomal localization, and tissue expression of autotaxin
RT   from human teratocarcinoma cells.";
RL   Biochem. Biophys. Res. Commun. 218:714-719(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), SUBCELLULAR LOCATION, ENZYME
RP   REGULATION, AND VARIANT PRO-493.
RX   PubMed=15769751; DOI=10.1074/jbc.M413183200;
RA   van Meeteren L.A., Ruurs P., Christodoulou E., Goding J.W.,
RA   Takakusa H., Kikuchi K., Perrakis A., Nagano T., Moolenaar W.H.;
RT   "Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-
RT   phosphate.";
RL   J. Biol. Chem. 280:21155-21161(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), PROTEIN SEQUENCE OF
RP   36-42 AND 49-54, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   TISSUE SPECIFICITY, AND VARIANT PRO-493.
RC   TISSUE=Brain, and Melanoma;
RX   PubMed=18175805; DOI=10.1074/jbc.M708705200;
RA   Giganti A., Rodriguez M., Fould B., Moulharat N., Coge F.,
RA   Chomarat P., Galizzi J.-P., Valet P., Saulnier-Blache J.-S.,
RA   Boutin J.A., Ferry G.;
RT   "Murine and human autotaxin alpha, beta, and gamma isoforms: gene
RT   organization, tissue distribution, and biochemical characterization.";
RL   J. Biol. Chem. 283:7776-7789(2008).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S.,
RA   Garber M., Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A.,
RA   Chang J.L., Cuomo C.A., Dewar K., FitzGerald M.G., Yang X.,
RA   Allen N.R., Anderson S., Asakawa T., Blechschmidt K., Bloom T.,
RA   Borowsky M.L., Butler J., Cook A., Corum B., DeArellano K.,
RA   DeCaprio D., Dooley K.T., Dorris L. III, Engels R., Gloeckner G.,
RA   Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K., Jaffe D.B.,
RA   Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C.,
RA   O'Leary S.B., O'Neill K., Parker S.C.J., Polley A., Raymond C.K.,
RA   Reichwald K., Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R.,
RA   Smith C.L., Sneddon T.P., Talamas J.A., Tenzin P., Topham K.,
RA   Venkataraman V., Wen G., Yamazaki S., Young S.K., Zeng Q.,
RA   Zimmer A.R., Rosenthal A., Birren B.W., Platzer M., Shimizu N.,
RA   Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   PRO-493.
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 36-49; 318-330; 335-344; 440-450 AND 854-863,
RP   IDENTIFICATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=12176993; DOI=10.1074/jbc.M205623200;
RA   Tokumura A., Majima E., Kariya Y., Tominaga K., Kogure K., Yasuda K.,
RA   Fukuzawa K.;
RT   "Identification of human plasma lysophospholipase D, a
RT   lysophosphatidic acid-producing enzyme, as autotaxin, a
RT   multifunctional phosphodiesterase.";
RL   J. Biol. Chem. 277:39436-39442(2002).
RN   [9]
RP   PROTEIN SEQUENCE OF 256-266; 370-392; 457-463; 481-496; 501-510;
RP   545-554; 639-643; 706-710 AND 829-840, FUNCTION, AND VARIANT PRO-493.
RC   TISSUE=Melanoma;
RX   PubMed=1733949;
RA   Stracke M.L., Krutzsch H.C., Unsworth E.J., Aarestad A., Cioce V.,
RA   Schiffmann E., Liotta L.A.;
RT   "Identification, purification, and partial sequence analysis of
RT   autotaxin, a novel motility-stimulating protein.";
RL   J. Biol. Chem. 267:2524-2529(1992).
RN   [10]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=11559573;
RA   Nam S.W., Clair T., Kim Y.S., McMarlin A., Schiffmann E., Liotta L.A.,
RA   Stracke M.L.;
RT   "Autotaxin (NPP-2), a metastasis-enhancing mitogen, is an angiogenic
RT   factor.";
RL   Cancer Res. 61:6938-6944(2001).
RN   [11]
RP   INDUCTION, AND POSSIBLE FUNCTION IN OBESITY.
RX   PubMed=15700135; DOI=10.1007/s00125-004-1660-8;
RA   Boucher J., Quilliot D., Pradere J.P., Simon M.F., Gres S., Guigne C.,
RA   Prevot D., Ferry G., Boutin J.A., Carpene C., Valet P.,
RA   Saulnier-Blache J.S.;
RT   "Potential involvement of adipocyte insulin resistance in obesity-
RT   associated up-regulation of adipocyte lysophospholipase D/autotaxin
RT   expression.";
RL   Diabetologia 48:569-577(2005).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, ENZYME REGULATION, AND MUTAGENESIS OF
RP   THR-210; PHE-211; ALA-218; ASN-231 AND TYR-307.
RX   PubMed=21240271; DOI=10.1038/nsmb.1980;
RA   Hausmann J., Kamtekar S., Christodoulou E., Day J.E., Wu T.,
RA   Fulkerson Z., Albers H.M., van Meeteren L.A., Houben A.J.,
RA   van Zeijl L., Jansen S., Andries M., Hall T., Pegg L.E., Benson T.E.,
RA   Kasiem M., Harlos K., Kooi C.W., Smyth S.S., Ovaa H., Bollen M.,
RA   Morris A.J., Moolenaar W.H., Perrakis A.;
RT   "Structural basis of substrate discrimination and integrin binding by
RT   autotaxin.";
RL   Nat. Struct. Mol. Biol. 18:198-204(2011).
CC   -!- FUNCTION: Hydrolyzes lysophospholipids to produce lysophosphatidic
CC       acid (LPA) in extracellular fluids. Major substrate is
CC       lysophosphatidylcholine. Also can act on
CC       sphingosylphosphphorylcholine producing sphingosine-1-phosphate, a
CC       modulator of cell motility. Can hydrolyze, in vitro, bis-pNPP, to
CC       some extent pNP-TMP, and barely ATP. Involved in several motility-
CC       related processes such as angiogenesis and neurite outgrowth. Acts
CC       as an angiogenic factor by stimulating migration of smooth muscle
CC       cells and microtubule formation. Stimulates migration of melanoma
CC       cells, probably via a pertussis toxin-sensitive G protein. May
CC       have a role in induction of parturition. Possible involvement in
CC       cell proliferation and adipose tissue development. Tumor cell
CC       motility-stimulating factor. {ECO:0000269|PubMed:11559573,
CC       ECO:0000269|PubMed:1733949, ECO:0000269|PubMed:21240271}.
CC   -!- CATALYTIC ACTIVITY: 1-alkyl-sn-glycero-3-phosphoethanolamine +
CC       H(2)O = 1-alkyl-sn-glycerol 3-phosphate + ethanolamine.
CC       {ECO:0000269|PubMed:21240271}.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000250};
CC       Note=Binds 2 Zn(2+) ions per subunit. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC       Note=Binds 1 Ca(2+) ion per subunit. {ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by lysophosphatidic acid (LPA) and
CC       sphingosine-1-phosphate (S1P). Inhibited by EDTA and EGTA
CC       (Probable). {ECO:0000305|PubMed:15769751,
CC       ECO:0000305|PubMed:18175805, ECO:0000305|PubMed:21240271}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.5 mM for 16:0-LPC (at pH 8.5) {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC         KM=5.5 mM for pNP-TMP (at pH 8.5) {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC         KM=11.3 mM for pNppp (isoform 1) {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC         KM=5.7 mM for pNppp (isoform 2) {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC         KM=19.8 mM for pNppp (isoform 3) {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC         Vmax=1.9 nmol/min/ug enzyme with pNppp as substrate (isoform 1)
CC         {ECO:0000269|PubMed:12176993, ECO:0000269|PubMed:18175805};
CC         Vmax=0.67 nmol/min/ug enzyme with pNppp as substrate (isoform 2)
CC         {ECO:0000269|PubMed:12176993, ECO:0000269|PubMed:18175805};
CC         Vmax=1.6 nmol/min/ug enzyme with pNppp as substrate (isoform 3)
CC         {ECO:0000269|PubMed:12176993, ECO:0000269|PubMed:18175805};
CC       pH dependence:
CC         Optimum pH is 9.0 (isoform 1), 8.0 (isoform 3). Isoform 1 is
CC         less sensitive to pH. Isoform 1, isoform 2 and isoform 3 all
CC         retain some activity at pH 9.5. {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC       Temperature dependence:
CC         Isoform 1 and isoform 3 are active from 45 to 60 degrees
CC         Celsius. {ECO:0000269|PubMed:12176993,
CC         ECO:0000269|PubMed:18175805};
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:15769751}.
CC       Note=Secreted by most body fluids including serum and CSF. Also by
CC       adipocytes and numerous cancer cells.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=ATXter, Beta;
CC         IsoId=Q13822-1; Sequence=Displayed;
CC       Name=2; Synonyms=ATXmel, Alpha;
CC         IsoId=Q13822-2; Sequence=VSP_006750;
CC       Name=3; Synonyms=Gamma;
CC         IsoId=Q13822-3; Sequence=VSP_036398;
CC         Note=Ref.5 (ABW38316) sequence is in conflict in position:
CC         23:N->S. Ref.5 (ABW38316) sequence is in conflict in position:
CC         291:Q->R. Ref.5 (ABW38316) sequence is in conflict in position:
CC         349:H->R. Ref.5 (ABW38316) sequence is in conflict in position:
CC         493:S->P. Ref.5 (ABW38316) sequence is in conflict in position:
CC         599:F->Y. Ref.5 (ABW38316) sequence is in conflict in position:
CC         602:S->T. Ref.5 (ABW38316) sequence is in conflict in position:
CC         654:P->L. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Predominantly expressed in brain, placenta,
CC       ovary, and small intestine. Expressed in a number of carcinomas
CC       such as hepatocellular and prostate carcinoma, neuroblastoma and
CC       non-small-cell lung cancer. Expressed in body fluids such as
CC       plasma, cerebral spinal fluid (CSF), saliva, follicular and
CC       amniotic fluids. Not detected in leukocytes. Isoform 1 is more
CC       highly expressed in peripheral tissues than in the central nervous
CC       system (CNS). Adipocytes only express isoform 1. Isoform 3 is more
CC       highly expressed in the brain than in peripheral tissues.
CC       {ECO:0000269|PubMed:18175805, ECO:0000269|PubMed:8579579,
CC       ECO:0000269|PubMed:8586446}.
CC   -!- INDUCTION: Up-regulated in massively obese subjects with glucose
CC       intolerance, and during adipogenesis.
CC       {ECO:0000269|PubMed:15700135}.
CC   -!- PTM: N-glycosylation, but not furin-cleavage, plays a critical
CC       role on secretion and on lysoPLD activity. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the nucleotide
CC       pyrophosphatase/phosphodiesterase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ENPP2ID40455ch8q24.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L35594; AAA64785.1; -; mRNA.
DR   EMBL; D45421; BAA08260.1; -; mRNA.
DR   EMBL; D45914; BAA08342.1; -; Genomic_DNA.
DR   EMBL; L46720; AAB00855.1; -; mRNA.
DR   EMBL; EU131011; ABW38316.2; -; mRNA.
DR   EMBL; AC099818; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107960; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC034961; AAH34961.1; -; mRNA.
DR   CCDS; CCDS34936.1; -. [Q13822-1]
DR   CCDS; CCDS47914.1; -. [Q13822-3]
DR   CCDS; CCDS6329.1; -. [Q13822-2]
DR   PIR; A55144; A55144.
DR   RefSeq; NP_001035181.1; NM_001040092.2. [Q13822-1]
DR   RefSeq; NP_001124335.1; NM_001130863.2. [Q13822-3]
DR   RefSeq; NP_006200.3; NM_006209.4. [Q13822-2]
DR   UniGene; Hs.190977; -.
DR   PDB; 4ZG6; X-ray; 1.80 A; A/B=17-863.
DR   PDB; 4ZG7; X-ray; 1.75 A; A=55-860.
DR   PDB; 4ZG9; X-ray; 2.95 A; A/B=1-863.
DR   PDB; 4ZGA; X-ray; 2.60 A; A=1-863.
DR   PDB; 5KXA; X-ray; 2.59 A; A=1-863.
DR   PDBsum; 4ZG6; -.
DR   PDBsum; 4ZG7; -.
DR   PDBsum; 4ZG9; -.
DR   PDBsum; 4ZGA; -.
DR   PDBsum; 5KXA; -.
DR   ProteinModelPortal; Q13822; -.
DR   SMR; Q13822; -.
DR   BioGrid; 111194; 3.
DR   IntAct; Q13822; 2.
DR   MINT; MINT-7969086; -.
DR   BindingDB; Q13822; -.
DR   ChEMBL; CHEMBL3691; -.
DR   GuidetoPHARMACOLOGY; 2901; -.
DR   SwissLipids; SLP:000000393; -.
DR   SwissLipids; SLP:000000641; -. [Q13822-1]
DR   iPTMnet; Q13822; -.
DR   PhosphoSitePlus; Q13822; -.
DR   BioMuta; ENPP2; -.
DR   DMDM; 290457674; -.
DR   EPD; Q13822; -.
DR   PeptideAtlas; Q13822; -.
DR   PRIDE; Q13822; -.
DR   DNASU; 5168; -.
DR   Ensembl; ENST00000075322; ENSP00000075322; ENSG00000136960. [Q13822-1]
DR   Ensembl; ENST00000259486; ENSP00000259486; ENSG00000136960. [Q13822-2]
DR   Ensembl; ENST00000522826; ENSP00000428291; ENSG00000136960. [Q13822-3]
DR   GeneID; 5168; -.
DR   KEGG; hsa:5168; -.
DR   UCSC; uc003yos.3; human. [Q13822-1]
DR   CTD; 5168; -.
DR   DisGeNET; 5168; -.
DR   GeneCards; ENPP2; -.
DR   H-InvDB; HIX0025550; -.
DR   HGNC; HGNC:3357; ENPP2.
DR   HPA; HPA023700; -.
DR   HPA; HPA053652; -.
DR   MIM; 601060; gene.
DR   neXtProt; NX_Q13822; -.
DR   OpenTargets; ENSG00000136960; -.
DR   PharmGKB; PA27792; -.
DR   GeneTree; ENSGT00760000119157; -.
DR   HOVERGEN; HBG051484; -.
DR   InParanoid; Q13822; -.
DR   KO; K01122; -.
DR   OMA; GMEDVTC; -.
DR   OrthoDB; EOG091G017X; -.
DR   PhylomeDB; Q13822; -.
DR   TreeFam; TF330032; -.
DR   BioCyc; MetaCyc:HS06258-MONOMER; -.
DR   BRENDA; 3.1.4.39; 2681.
DR   Reactome; R-HSA-199220; Vitamin B5 (pantothenate) metabolism.
DR   SABIO-RK; Q13822; -.
DR   ChiTaRS; ENPP2; human.
DR   GeneWiki; Autotaxin; -.
DR   GenomeRNAi; 5168; -.
DR   PRO; PR:Q13822; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000136960; -.
DR   CleanEx; HS_ENPP2; -.
DR   ExpressionAtlas; Q13822; baseline and differential.
DR   Genevisible; Q13822; HS.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; TAS:ProtInc.
DR   GO; GO:0047391; F:alkylglycerophosphoethanolamine phosphodiesterase activity; IEA:UniProtKB-EC.
DR   GO; GO:0005509; F:calcium ion binding; ISS:UniProtKB.
DR   GO; GO:0016787; F:hydrolase activity; TAS:UniProtKB.
DR   GO; GO:0004622; F:lysophospholipase activity; IDA:UniProtKB.
DR   GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR   GO; GO:0004551; F:nucleotide diphosphatase activity; TAS:ProtInc.
DR   GO; GO:0004528; F:phosphodiesterase I activity; TAS:ProtInc.
DR   GO; GO:0030247; F:polysaccharide binding; IEA:InterPro.
DR   GO; GO:0005044; F:scavenger receptor activity; IEA:InterPro.
DR   GO; GO:0008134; F:transcription factor binding; TAS:ProtInc.
DR   GO; GO:0008270; F:zinc ion binding; ISS:UniProtKB.
DR   GO; GO:0048870; P:cell motility; TAS:UniProtKB.
DR   GO; GO:0006935; P:chemotaxis; NAS:UniProtKB.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0006955; P:immune response; IEA:InterPro.
DR   GO; GO:0006796; P:phosphate-containing compound metabolic process; TAS:ProtInc.
DR   GO; GO:0034638; P:phosphatidylcholine catabolic process; IDA:UniProtKB.
DR   GO; GO:0009395; P:phospholipid catabolic process; IDA:UniProtKB.
DR   GO; GO:0010634; P:positive regulation of epithelial cell migration; IMP:UniProtKB.
DR   GO; GO:2000394; P:positive regulation of lamellipodium morphogenesis; IGI:UniProtKB.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0045765; P:regulation of angiogenesis; IEA:InterPro.
DR   GO; GO:0030334; P:regulation of cell migration; IDA:UniProtKB.
DR   Gene3D; 3.40.720.10; -; 1.
DR   InterPro; IPR017849; Alkaline_Pase-like_a/b/a.
DR   InterPro; IPR017850; Alkaline_phosphatase_core.
DR   InterPro; IPR001604; DNA/RNA_non-sp_Endonuclease.
DR   InterPro; IPR029881; ENPP2.
DR   InterPro; IPR020821; Extracellular_endonuc_su_A.
DR   InterPro; IPR002591; Phosphodiest/P_Trfase.
DR   InterPro; IPR020436; Somatomedin_B_chordata.
DR   InterPro; IPR001212; Somatomedin_B_dom.
DR   PANTHER; PTHR10151:SF96; PTHR10151:SF96; 1.
DR   Pfam; PF01223; Endonuclease_NS; 1.
DR   Pfam; PF01663; Phosphodiest; 1.
DR   Pfam; PF01033; Somatomedin_B; 2.
DR   PRINTS; PR00022; SOMATOMEDINB.
DR   SMART; SM00892; Endonuclease_NS; 1.
DR   SMART; SM00477; NUC; 1.
DR   SMART; SM00201; SO; 2.
DR   SUPFAM; SSF53649; SSF53649; 1.
DR   SUPFAM; SSF90188; SSF90188; 2.
DR   PROSITE; PS00524; SMB_1; 2.
DR   PROSITE; PS50958; SMB_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Chemotaxis;
KW   Cleavage on pair of basic residues; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Glycoprotein; Hydrolase;
KW   Lipid degradation; Lipid metabolism; Metal-binding; Obesity;
KW   Polymorphism; Reference proteome; Repeat; Secreted; Signal; Zinc.
FT   SIGNAL        1     27       {ECO:0000250}.
FT   PROPEP       28     35       Removed by furin.
FT                                {ECO:0000269|PubMed:12176993,
FT                                ECO:0000269|PubMed:18175805}.
FT                                /FTId=PRO_0000281649.
FT   CHAIN        36    863       Ectonucleotide
FT                                pyrophosphatase/phosphodiesterase family
FT                                member 2.
FT                                /FTId=PRO_0000188567.
FT   DOMAIN       55     98       SMB 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00350}.
FT   DOMAIN       99    143       SMB 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00350}.
FT   REGION      211    214       Substrate binding. {ECO:0000250}.
FT   REGION      244    255       Substrate binding. {ECO:0000250}.
FT   REGION      830    851       Required for secretion. {ECO:0000250}.
FT   MOTIF       127    129       Cell attachment site. {ECO:0000255}.
FT   ACT_SITE    210    210       Nucleophile. {ECO:0000250}.
FT   METAL       172    172       Zinc 1; catalytic. {ECO:0000250}.
FT   METAL       210    210       Zinc 1; catalytic. {ECO:0000250}.
FT   METAL       312    312       Zinc 2; catalytic. {ECO:0000250}.
FT   METAL       316    316       Zinc 2; catalytic. {ECO:0000250}.
FT   METAL       316    316       Zinc 2; via tele nitrogen; catalytic.
FT                                {ECO:0000250}.
FT   METAL       359    359       Zinc 1; catalytic. {ECO:0000250}.
FT   METAL       360    360       Zinc 1; catalytic. {ECO:0000250}.
FT   METAL       360    360       Zinc 1; via tele nitrogen; catalytic.
FT                                {ECO:0000250}.
FT   METAL       475    475       Zinc 2; catalytic. {ECO:0000250}.
FT   METAL       475    475       Zinc 2; via tele nitrogen; catalytic.
FT                                {ECO:0000250}.
FT   METAL       740    740       Calcium. {ECO:0000250}.
FT   METAL       744    744       Calcium. {ECO:0000250}.
FT   METAL       746    746       Calcium; via carbonyl oxygen.
FT                                {ECO:0000250}.
FT   METAL       748    748       Calcium. {ECO:0000250}.
FT   BINDING     231    231       Substrate. {ECO:0000250}.
FT   BINDING     307    307       Substrate. {ECO:0000250}.
FT   SITE        853    853       Essential for catalytic activity.
FT                                {ECO:0000250}.
FT   CARBOHYD     54     54       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    411    411       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    525    525       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    807    807       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID     59     76       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID     63     94       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID     74     87       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID     80     86       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    103    120       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    108    138       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    118    131       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    124    130       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    149    195       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    157    351       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    367    469       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    414    806       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    567    667       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    569    652       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   DISULFID    775    785       {ECO:0000255|PROSITE-ProRule:PRU00350}.
FT   VAR_SEQ     324    324       E -> EESSYGSPFTPAKRPKRKVAPKRRQERPVAPPKKRR
FT                                RKIHRMDHYAAETRQDK (in isoform 2).
FT                                {ECO:0000303|PubMed:18175805,
FT                                ECO:0000303|PubMed:7982964}.
FT                                /FTId=VSP_006750.
FT   VAR_SEQ     593    593       E -> EAETRKFRGSRNENKENINGNFEPRK (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:18175805}.
FT                                /FTId=VSP_036398.
FT   VARIANT     493    493       S -> P (in dbSNP:rs10283100).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:15769751,
FT                                ECO:0000269|PubMed:1733949,
FT                                ECO:0000269|PubMed:18175805,
FT                                ECO:0000269|PubMed:7982964,
FT                                ECO:0000269|PubMed:8579579,
FT                                ECO:0000269|PubMed:8586446}.
FT                                /FTId=VAR_060469.
FT   VARIANT     577    577       N -> S (in dbSNP:rs2289886).
FT                                /FTId=VAR_057472.
FT   VARIANT     726    726       S -> L (in dbSNP:rs16892767).
FT                                /FTId=VAR_057473.
FT   MUTAGEN     170    170       S->E: Reduces lysophospholipase activity
FT                                by about 70%.
FT   MUTAGEN     210    210       T->A: Loss of lysophospholipase activity.
FT                                {ECO:0000269|PubMed:21240271}.
FT   MUTAGEN     211    211       F->Y: Reduces lysophospholipase activity
FT                                by about 70%.
FT                                {ECO:0000269|PubMed:21240271}.
FT   MUTAGEN     218    218       A->V: Reduces lysophospholipase activity
FT                                by about 50%.
FT                                {ECO:0000269|PubMed:21240271}.
FT   MUTAGEN     231    231       N->A: Strongly reduced lysophospholipase
FT                                activity. {ECO:0000269|PubMed:21240271}.
FT   MUTAGEN     307    307       Y->Q: Reduces lysophospholipase activity
FT                                by about 70%.
FT                                {ECO:0000269|PubMed:21240271}.
FT   CONFLICT     23     23       N -> S (in Ref. 1; AAA64785 and 5;
FT                                ABW38316). {ECO:0000305}.
FT   CONFLICT     73     73       D -> H (in Ref. 2; BAA08260).
FT                                {ECO:0000305}.
FT   CONFLICT    100    100       G -> A (in Ref. 3; AAB00855).
FT                                {ECO:0000305}.
FT   CONFLICT    291    291       Q -> R (in Ref. 1; AAA64785 and 5;
FT                                ABW38316). {ECO:0000305}.
FT   CONFLICT    349    349       H -> R (in Ref. 1; AAA64785 and 5;
FT                                ABW38316). {ECO:0000305}.
FT   CONFLICT    457    457       K -> P (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    501    501       V -> S (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    508    508       E -> N (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    554    554       P -> L (in Ref. 9; AA sequence).
FT                                {ECO:0000305}.
FT   CONFLICT    629    629       P -> L (in Ref. 1; AAA64785 and 5;
FT                                ABW38316). {ECO:0000305}.
FT   CONFLICT    644    644       S -> R (in Ref. 2; BAA08260).
FT                                {ECO:0000305}.
FT   CONFLICT    703    703       V -> A (in Ref. 2; BAA08260).
FT                                {ECO:0000305}.
FT   CONFLICT    769    769       Y -> H (in Ref. 2; BAA08260).
FT                                {ECO:0000305}.
FT   TURN         60     64       {ECO:0000244|PDB:4ZG7}.
FT   HELIX        80     83       {ECO:0000244|PDB:4ZG7}.
FT   HELIX        90     94       {ECO:0000244|PDB:4ZG7}.
FT   TURN         99    101       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       105    107       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      116    119       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      121    123       {ECO:0000244|PDB:4ZG9}.
FT   HELIX       124    127       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       134    138       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       144    146       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      166    172       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       176    181       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       182    185       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       187    195       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      196    198       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       210    219       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       223    226       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      230    235       {ECO:0000244|PDB:4ZG7}.
FT   TURN        236    239       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      240    242       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      244    247       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       248    250       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       252    254       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      255    257       {ECO:0000244|PDB:4ZG9}.
FT   HELIX       260    266       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      278    280       {ECO:0000244|PDB:4ZGA}.
FT   HELIX       282    292       {ECO:0000244|PDB:4ZG7}.
FT   TURN        297    299       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      302    311       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       312    318       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       323    325       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       326    345       {ECO:0000244|PDB:4ZG7}.
FT   TURN        349    351       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      353    359       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      369    372       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       373    375       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       380    382       {ECO:0000244|PDB:4ZG6}.
FT   STRAND      383    386       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      388    399       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       405    412       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      420    425       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       426    428       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       431    433       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      443    448       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      453    457       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      472    474       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       482    484       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      488    492       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      497    500       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       506    508       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       509    516       {ECO:0000244|PDB:4ZG7}.
FT   TURN        528    531       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       532    534       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      535    537       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       560    562       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       593    596       {ECO:0000244|PDB:4ZG6}.
FT   STRAND      610    614       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      619    623       {ECO:0000244|PDB:4ZG7}.
FT   TURN        624    627       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      628    636       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       647    649       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       661    663       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       667    672       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      677    682       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       684    686       {ECO:0000244|PDB:4ZG7}.
FT   TURN        690    692       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       693    696       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       699    701       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      702    705       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       707    718       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       720    728       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      730    738       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      744    746       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       750    752       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      766    777       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       782    784       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      789    797       {ECO:0000244|PDB:4ZG7}.
FT   TURN        806    809       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       812    814       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       816    822       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       827    834       {ECO:0000244|PDB:4ZG7}.
FT   STRAND      841    844       {ECO:0000244|PDB:4ZG7}.
FT   HELIX       846    854       {ECO:0000244|PDB:4ZG7}.
SQ   SEQUENCE   863 AA;  98994 MW;  94A7A2B3701F0993 CRC64;
     MARRSSFQSC QIISLFTFAV GVNICLGFTA HRIKRAEGWE EGPPTVLSDS PWTNISGSCK
     GRCFELQEAG PPDCRCDNLC KSYTSCCHDF DELCLKTARG WECTKDRCGE VRNEENACHC
     SEDCLARGDC CTNYQVVCKG ESHWVDDDCE EIKAAECPAG FVRPPLIIFS VDGFRASYMK
     KGSKVMPNIE KLRSCGTHSP YMRPVYPTKT FPNLYTLATG LYPESHGIVG NSMYDPVFDA
     TFHLRGREKF NHRWWGGQPL WITATKQGVK AGTFFWSVVI PHERRILTIL QWLTLPDHER
     PSVYAFYSEQ PDFSGHKYGP FGPEMTNPLR EIDKIVGQLM DGLKQLKLHR CVNVIFVGDH
     GMEDVTCDRT EFLSNYLTNV DDITLVPGTL GRIRSKFSNN AKYDPKAIIA NLTCKKPDQH
     FKPYLKQHLP KRLHYANNRR IEDIHLLVER RWHVARKPLD VYKKPSGKCF FQGDHGFDNK
     VNSMQTVFVG YGSTFKYKTK VPPFENIELY NVMCDLLGLK PAPNNGTHGS LNHLLRTNTF
     RPTMPEEVTR PNYPGIMYLQ SDFDLGCTCD DKVEPKNKLD ELNKRLHTKG STEERHLLYG
     RPAVLYRTRY DILYHTDFES GYSEIFLMPL WTSYTVSKQA EVSSVPDHLT SCVRPDVRVS
     PSFSQNCLAY KNDKQMSYGF LFPPYLSSSP EAKYDAFLVT NMVPMYPAFK RVWNYFQRVL
     VKKYASERNG VNVISGPIFD YDYDGLHDTE DKIKQYVEGS SIPVPTHYYS IITSCLDFTQ
     PADKCDGPLS VSSFILPHRP DNEESCNSSE DESKWVEELM KMHTARVRDI EHLTSLDFFR
     KTSRSYPEIL TLKTYLHTYE SEI
//
